title: Safety and efficacy of sirolimus-eluting stent in patients with acute coronary syndrome undergoing emergency procedure.
abstract: BACKGROUND
  Sirolimus-eluting stents (SES) reduce restenosis and revascularization rates, compared with bare-metal stents (BMS), in elective percutaneous coronary intervention (PCI). This study investigated the safety and efficacy of SES for emergency PCI in acute coronary syndrome (ACS) patients.
  
  
  RESULTS
  The 154 consecutive patients (SES: n=77, BMS: n=77) admitted to hospital with ACS were enrolled in this study. Procedural success (%DS <50%, Thrombolysis In Myocardial Infarction grade 3), major adverse cardiac events (MACE) at 30 days and 8 months, and the incidence of stent thrombosis were evaluated. There was no difference between the groups regarding procedural success. Patients treated with SES had smaller stent diameter (SES 3.04 mm vs BMS 3.24 mm; p=0.01) and longer stent length (25.7 mm vs 21.2 mm; p=0.01). At 30 days, there was no difference between the groups in the incidence of cardiovascular events. At 8 months, patients treated with the SES had a lower rate of repeat PCI (5.6% vs 18.6%; p=0.04) and MACE (9.7% vs 27.1%; p=0.01). Stent thrombosis was no different between groups (1.4% vs 2.9%).
  
  
  CONCLUSIONS
  In emergency PCI for ACS patients, SES implantation significantly reduced cardiovascular events, compared with BMS, by decreasing the incidence of repeat PCI. The safety profile of SES is equal to that of BMS.
authors.affiliation: Department of Cardiology, Kawaguchi Municipal Medical Center, 180 Nishi-araijuku, Kawaguchi 333-0833, Japan. nmt-k@hotmail.co.jp
authors.forename: Kazumiki
authors.initials: K
authors.lastname: Nomoto
authors.forename: Ikuyoshi
authors.initials: I
authors.lastname: Watanabe
authors.forename: Tomiya
authors.initials: T
authors.lastname: Oba
authors.forename: Ken
authors.initials: K
authors.lastname: Nagao
authors.forename: Toshio
authors.initials: T
authors.lastname: Kushiro
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hirayama
mesh_terms: D054058:Acute Coronary Syndrome / Q000401:mortality / Q000628:therapy*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents / Q000009:adverse effects / Q000706:statistics & numerical data; D004632:Emergency Medical Services; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007564:Japan / Q000453:epidemiology; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus